

Corporation obtaining approval, the name of its representative, and the address of its main office

Applicant Name: Merial Japan Ltd.

Michel Lachaussee, President (Seal)

Address: Sanno Grand Bldg. 8F, 2-14-2 Nagata-cho, Chiyoda-ku, Tokyo

Approved Type 1 Use Regulation

Name of the Type of Living Modified Organism	Canarypox virus ALVAC to which a protective antigen protein expression gene derived from feline leukemia virus (vCP97 strain) was transferred (FeLV- <i>env</i> , <i>gag</i> , <i>pol</i> , Canarypox virus)
Content of the Type 1 Use of Living Modified Organism	<p>(1) Transportation and storage (including transportation and storage of inoculated animals with the viable, modified live vaccine)</p> <p>(2) In case of a study to collect data on clinical research, which must be submitted as specified by Article 14 Paragraph 3 of the Pharmaceutical Affairs Law (hereinafter referred to as "clinical trial"), use in accordance with the notification of the clinical trial plan submitted according to Article 80-2 Paragraph 2 of the said Law and the protocol prepared according to Article 7 of the Ordinance for good clinical practice of new animal drugs (Ordinance of the Ministry of Agriculture, Forestry and Fisheries No. 75 of 1997)</p> <p>(3) Use in accordance with the application for approval as specified by Article 14 Paragraph 1 of the Pharmaceutical Affairs Law [except operations relevant to (4)]</p> <p>(4) Vaccination (excluding those involving human food)</p> <p>(5) Disposal of devices and residues after inoculation in accordance with the standard for disposal of infectious industrial waste provided in Article 12-2 of the Waste Disposal and Public Cleansing Law (Law No.137 of 1970)</p> <p>(6) Disposal excluding those in (5) (including cases that accompany the disposal of inoculated animals carrying the viable modified live vaccine)</p> <p>(7) Acts incidental to (1) to (6)</p>
Method of the Type 1 Use of Living Modified Organism	-